EGFR and non-small cell lung carcinoma: The ORIENT-31 trial, a prospective, double-blind, phase 3 clinical trial, evaluated the efficacy and safety of sintilimab with or without bevacizumab biosimilar IBI305 plus pemetrexed and cisplatin, compared with pemetrexed and cisplatin alone, for patients with locally advanced or metastatic EGFR-mutated NSCLC who had disease progression after receiving EGFR TKI therapy (11).